Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.42 |
| ▸ | CHRNG | P07510 | 1/20 | 0.42 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CHRND | Q07001 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5650431 | 0.91 | SLC6A2 (0.40) | LMNASMN1; SMN2MAPTGAASLC6A2 | |
| SCHEMBL2084708 | 0.91 | SLC6A2 (0.40) | LMNASMN1; SMN2MAPTGAASLC6A2 | |
| SCHEMBL22613508 | 0.83 | ALDH1A1 (0.45) | LMNASMN1; SMN2MAPTGAASLC6A2 | |
| SCHEMBL9778811 | 0.80 | MAOB (0.51) | SMN1; SMN2MAPTMAOBMAOAACHE | |
| SCHEMBL4588500 | 0.79 | ESR2 (0.41) | LMNASMN1; SMN2MAPTGAATSHR | |
| SCHEMBL2084415 | 0.79 | LMNA (0.54) | LMNASMN1; SMN2MAPTSLC6A2SLC6A3 | |
| SCHEMBL3884112 | 0.79 | CYP19A1 (0.40) | LMNASMN1; SMN2MAPTGAATSHR | |
| SCHEMBL587682 | 0.79 | TAAR1 (0.42) | LMNASMN1; SMN2MAPTGAATSHR | |
| SCHEMBL9047543 | 0.79 | TSHR (0.38) | LMNASMN1; SMN2MAPTGAASLC6A3 | |
| SCHEMBL1932565 | 0.79 | TSHR (0.38) | LMNASMN1; SMN2MAPTGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | claimed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | claimed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | claimed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | claimed |
| US-11586060-B2 | Optical filter with light source | SOLUTIA CANADA INC. (CA) | 2023-02-21 | — | — | US | disclosed |
| US-10310300-B2 | Optical filter with light source | SWITCH MATERIALS, INC. (CA) | 2019-06-04 | — | — | US | disclosed |
| US-20180210240-A1 | OPTICAL FILTER WITH LIGHT SOURCE | SWITCH MATERIALS, INC. (CA) | 2018-07-26 | — | — | US | disclosed |
| US-9910301-B2 | Switchable optical filter apparatus with light | SWITCH MATERIALS, INC. (CA) | 2018-03-06 | — | — | US | disclosed |
| US-20170341069-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | UNIV CALIFORNIA (US) | 2017-11-30 | — | — | US | disclosed |
| US-20160339418-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | LIPSHUTZ BRUCE H (US) | 2016-11-24 | — | — | US | disclosed |
| US-20160083398-A1 | DIARYLETHENE COMPOUNDS AND USES THEREOF | SWITCH MATERIALS, INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-9227986-B2 | Diarylethene compounds and uses thereof | SWITCH MATERIALS, INC. (CA) | 2016-01-05 | — | — | US | disclosed |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | CORTICAL PTY LTD (AU) | 2010-12-23 | — | — | US | disclosed |
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007057658-A1 | PALLADIUM CATALYSED HECK ARYLATION OR VINYLATION OF 1-SUBSTITUTED OLEFINS | THE UNIVERSITY OF LIVERPOOL (GB) | 2007-05-24 | — | — | WO | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | CORTICAL PTY LTD (AU) | 2007-01-11 | — | — | US | disclosed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160339418-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | SOD1, MPO, TFRC | LMNA 4661/4885SMN1; SMN2 1715/4885MAPT 2722/4885 |
| US-20070010563-A1 | Novel methods for the treatment of inflammatory diseases | MIF, CCL2, CCL11 | LMNA 3675/4885SMN1; SMN2 3289/4885MAPT 3891/4885 |
| US-20100324001-A1 | Novel Methods for the Treatment of Inflammatory Diseases | MIF, CCL2, CCL11 | LMNA 3675/4885SMN1; SMN2 3289/4885MAPT 3891/4885 |
| US-20160083398-A1 | DIARYLETHENE COMPOUNDS AND USES THEREOF | KCNH2, KCNH3, SCN2B | LMNA 2312/4885SMN1; SMN2 4872/4885MAPT 4557/4885 |
| US-20170341069-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | SOD1, MPO, TFRC | LMNA 4670/4885SMN1; SMN2 1752/4885MAPT 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.